155 related articles for article (PubMed ID: 23618355)
1. Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome.
de Castro CV; Guimaraes G; Aguiar S; Lopes A; Baiocchi G; da Cunha IW; Campos AH; Soares FA; Begnami MD
Hum Pathol; 2013 Sep; 44(9):1747-55. PubMed ID: 23618355
[TBL] [Abstract][Full Text] [Related]
2. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor (EGFR) status in chordoma.
Ptaszyński K; Szumera-Ciećkiewicz A; Owczarek J; Mrozkowiak A; Pekul M; Barańska J; Rutkowski P
Pol J Pathol; 2009; 60(2):81-7. PubMed ID: 19886182
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma.
Fasig JH; Dupont WD; LaFleur BJ; Olson SJ; Cates JM
Neuropathol Appl Neurobiol; 2008 Feb; 34(1):95-104. PubMed ID: 17973908
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies.
Weinberger PM; Yu Z; Kowalski D; Joe J; Manger P; Psyrri A; Sasaki CT
Arch Otolaryngol Head Neck Surg; 2005 Aug; 131(8):707-11. PubMed ID: 16103303
[TBL] [Abstract][Full Text] [Related]
6. Oncogene alterations in endometrial carcinosarcomas.
Biscuola M; Van de Vijver K; Castilla MÁ; Romero-Pérez L; López-García MÁ; Díaz-Martín J; Matias-Guiu X; Oliva E; Palacios Calvo J
Hum Pathol; 2013 May; 44(5):852-9. PubMed ID: 23199529
[TBL] [Abstract][Full Text] [Related]
7. Expression of PDGFR-α, EGFR and c-MET in spinal chordoma: a series of 52 patients.
Akhavan-Sigari R; Gaab MR; Rohde V; Abili M; Ostertag H
Anticancer Res; 2014 Feb; 34(2):623-30. PubMed ID: 24510991
[TBL] [Abstract][Full Text] [Related]
8. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
[TBL] [Abstract][Full Text] [Related]
9. Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR.
Schirosi L; Lantuejoul S; Cavazza A; Murer B; Yves Brichon P; Migaldi M; Sartori G; Sgambato A; Rossi G
Am J Surg Pathol; 2008 Nov; 32(11):1627-42. PubMed ID: 18753943
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.
Akhavan-Sigari R; Abili M; Gaab MR; Rohde V; Zafar N; Emami P; Ostertag H
Neurosurg Rev; 2015 Jan; 38(1):89-98; discussion 98-9. PubMed ID: 25323095
[TBL] [Abstract][Full Text] [Related]
11. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.
Tamborini E; Miselli F; Negri T; Lagonigro MS; Staurengo S; Dagrada GP; Stacchiotti S; Pastore E; Gronchi A; Perrone F; Carbone A; Pierotti MA; Casali PG; Pilotti S
Clin Cancer Res; 2006 Dec; 12(23):6920-8. PubMed ID: 17145809
[TBL] [Abstract][Full Text] [Related]
12. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.
Tamborini E; Virdis E; Negri T; Orsenigo M; Brich S; Conca E; Gronchi A; Stacchiotti S; Manenti G; Casali PG; Pierotti MA; Pilotti S
Neuro Oncol; 2010 Aug; 12(8):776-89. PubMed ID: 20164240
[TBL] [Abstract][Full Text] [Related]
13. Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein.
Ostroumov E; Hunter CJ
Spine (Phila Pa 1976); 2008 Dec; 33(25):2774-80. PubMed ID: 19050584
[TBL] [Abstract][Full Text] [Related]
14. Expression of receptor tyrosine kinases in esophageal carcinosarcoma.
Sano A; Sakurai S; Kato H; Suzuki S; Yokobori T; Sakai M; Tanaka N; Inose T; Sohda M; Nakajima M; Fukai Y; Miyazaki T; Ojima H; Hosoya Y; Enomoto T; Kanda T; Ajioka Y; Kuwano H
Oncol Rep; 2013 Jun; 29(6):2119-26. PubMed ID: 23546020
[TBL] [Abstract][Full Text] [Related]
15. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
Orzan F; Terreni MR; Longoni M; Boari N; Mortini P; Doglioni C; Riva P
Oncol Rep; 2007 Jul; 18(1):249-52. PubMed ID: 17549375
[TBL] [Abstract][Full Text] [Related]
16. Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma.
Liang C; Ma Y; Yong L; Yang C; Wang P; Liu X; Zhu B; Zhou H; Liu X; Liu Z
Cancer Sci; 2019 Jan; 110(1):166-179. PubMed ID: 30426615
[TBL] [Abstract][Full Text] [Related]
17. Does insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study.
Scheipl S; Froehlich EV; Leithner A; Beham A; Quehenberger F; Mokry M; Stammberger H; Varga PP; Lazáry A; Windhager R; Gattenloehner S; Liegl B
Histopathology; 2012 May; 60(6):999-1003. PubMed ID: 22372631
[TBL] [Abstract][Full Text] [Related]
18. Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in chordomas is correlated to c-MET expression.
Walter BA; Begnami M; Valera VA; Santi M; Rushing EJ; Quezado M
J Neurooncol; 2011 Jan; 101(2):199-206. PubMed ID: 20617367
[TBL] [Abstract][Full Text] [Related]
19. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.
Froehlich EV; Scheipl S; Lazàry A; Varga PP; Schmid C; Stammberger H; Beham A; Bodo K; Schroettner H; Quehenberger F; Windhager R; Liegl B; Leithner A
Spine (Phila Pa 1976); 2012 Jun; 37(13):E757-67. PubMed ID: 22228328
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer.
Kurokawa Y; Matsuura N; Kawabata R; Nishikawa K; Ebisui C; Yokoyama Y; Shaker MN; Hamakawa T; Takahashi T; Takiguchi S; Mori M; Doki Y
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S584-90. PubMed ID: 24743909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
